Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 5 TO FORM S-1 - Biostage, Inc. | v339095_s1a.htm |
| EX-4.2 - FORM OF SHAREHOLDERS RIGHTS AGREEMENT - Biostage, Inc. | v339095_ex4-2.htm |
| EX-5.1 - OPINION OF BURNS & LEVINSON LLP - Biostage, Inc. | v339095_ex5-1.htm |
| EX-3.5 - FORM OF CERTIFICATE OF DESIGNATIONS - Biostage, Inc. | v339095_ex3-5.htm |
| EX-4.1 - SPECIMEN STOCK CERTIFICATE - Biostage, Inc. | v339095_ex4-1.htm |
| EX-10.7 - FORM OF 2013 EQUITY INCENTIVE PLAN - Biostage, Inc. | v339095_ex10-7.htm |
| EX-10.14 - DIRECTOR COMPENSATION ARRANGEMENTS - Biostage, Inc. | v339095_ex10-14.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Harvard Bioscience, Inc.:
We consent to the use of our report dated February 28, 2013, with respect to the balance sheets of Harvard Apparatus Regenerative Technology, Inc., a business segment of Harvard Bioscience, Inc. and development stage company, as of December 31, 2012 and 2011, and the related statements of operations, invested equity (deficit), and cash flows for the years ended December 31, 2012, 2011 and 2010, and for the period from February 24, 2009 (inception) to December 31, 2012, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
March 25, 2013